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bstract
Mutations in the gene encoding beta-glucocerebrosidase, a lysosomal degrading enzyme, have recently been associated with the development
f Parkinson disease.
Here we report the results found in a cohort of Portuguese Parkinson disease patients and healthy age-matched controls for mutations in the
forementioned gene. This screening was accomplished by sequencing the complete open-reading frame, as well as intron/exon boundaries,
f the glucocerebrosidase gene, in a total of 230 patients and 430 controls.
We have found an increased number of Parkinson disease patients presenting mutations in GBA when compared to controls.
These results, together with recent literature, clearly suggest a role of glucocerebrosidase in the development of Parkinson disease.
2007 Elsevier Inc. All rights reserved.
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. Introduction
Mutations and complex rearrangements in the gene encod-
ng -glucocerebrosidase (GBA) cause Gaucher disease
GD), an autosomal recessive lysosomal storage disorder
ften categorized in three main sub-types: nonneurono-
athic type 1, acute neuronopathic type 2 and subacute
euronopathic type 3. The clinical features in patients with
D vary greatly, ranging from asymptomatic octogenari-
ns to severely affected infants with hepatosplenomegaly,
evelopmental regression and growth arrest. The symptomsPlease cite this article in press as: Bras, J., et al., Complete screening for
Portugal, Neurobiol Aging (2007), doi:10.1016/j.neurobiolaging.2007.1
ncountered in GD do not typically overlap significantly with
hose seen in patients with Parkinson disease (PD). However,
∗ Corresponding author at: Laboratory of Neurogenetics, National Insti-
utes on Aging, National Institutes of Health, Building 35, Room 1A1014,
5 Lincoln Drive, Bethesda, MD 20892, USA. Tel.: +1 301 451 6079;
ax: +1 301 451 5466.
E-mail address: singleta@mail.nih.gov (A. Singleton).
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oi:10.1016/j.neurobiolaging.2007.11.016here have been reports describing rare patients with GD who
evelop manifestations of PD. This prompted researchers to
xplore the prevalence of mutations in GBA among subjects
ith PD; the startling association between GBA mutations
nd PD in brain bank samples (Lwin et al., 2004) led others
o assess Jewish and non-Jewish populations (Aharon-Peretz
t al., 2004; Ziegler et al., 2007). Several replication studies
ave been published with positive and negative associations;
he relative rarity of mutations and the complexity of the
enomic region where GBA is associated resulted in stud-
es that were underpowered or were focused only on specific
utations.
. Materials and methodsglucocerebrosidase mutations in Parkinson disease patients from
1.016
Here we report the results of complete sequence analy-
is of GBA in a series of 230 Portuguese patients with PD,
ollected sequentially at the Coimbra University Hospital in
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Table 1
Variants found
Mutations PD patients Controls
Proteina Allele nameb N % of all cases % of carriers N % of all controls % of carriers
N409S N370S 5 2.2 35.7 3 0.7 100
N435T N396T 5 2.2 35.7 0 – –
D448H D409H 1 0.4 7.1 0 – –
L483P L444P 3 1.3 21.4 0 – –
Polymorphic variants
K13R K(−27)R 1 0.4 20 0 – –
R41Lc R2Lc 0 – – 1 0.2 9.1
E365K E326K 2 0.9 40 3 0.7 27.3
T408M T369M 2 0.9 40 5 1.2 45.5
E427Kc E388Kc 0 – – 2 0.5 18.2
As described in the text, all variants were present in heterozygous state.
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ta Amino acid designations are based on the primary GBA translation prod
b Common nomenclature attributed to mutations; does not include the 39-
c These represent previously unpublished mutations, therefore pathogenic
ortugal and in 430 healthy age-matched controls. All sub-
ects were Caucasian and of apparent Portuguese ancestry.
iagnosis was made in accordance with the UK Brain Bank
riteria. Family history was considered positive if at least one
amily member presented with PD. The entire coding region
nd the exon/intron boundaries of GBA gene were sequenced
n all subjects (details available upon request). To exclude
alse positives due to co-amplification of the pseudogene, all
utations were confirmed by sequencing bands excised from
n agarose gel, following PCR amplification of a fresh DNA
liquot.
. Results
The PD group yielded 14 carriers of previously described
athogenic GBA mutations (N370S, N396T, D409H and
444P), all heterozygous, while the control group yielded
N370S carriers, also heterozygotes (Table 1). Two variants,
326K and T369M, previously described as non-pathogenic
olymorphisms, were identified in both patients and controls.
n addition, 2 novel variants and one previously described
ariant of unknown significance were identified (p.K13R;
.R41L and p.E427K) (Rozenberg et al., 2006).
. Discussion
We found a frequency of 6.1% (14/230) known pathogenic
utations in the PD series and 0.7% (3/430) in the control
roup. These results represent a significantly higher fre-
uency of mutations in GBA in PD patients when compared
o controls (p < 0.001; OR = 9.2; 95% CI 2.6–32.4). Of note,
he control group shows no mutations associated with severe
D; while they exist in the PD group—4/14 patients withPlease cite this article in press as: Bras, J., et al., Complete screening for
Portugal, Neurobiol Aging (2007), doi:10.1016/j.neurobiolaging.2007.1
444P or D409H. If we consider the variants of unknown
athogenicity (p.K13R; p.R41L and p.E427K) as potentially
ausative, this association still remains (p < 0.001; OR = 4.9;
5% CI 1.9–12.9).
w
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pluding the 39-residue signal peptide.
signal peptide.
unctional effects are unknown.
The most common mutation identified was N370S, the
ost frequently identified pathogenic mutation in Ashkenazi
ewish as well as Portuguese patients with GD. Based on
creening of 2000 random cord blood samples in Portugal, the
arrier frequency of this mutation is estimated to be 0.0043
n this population (Lacerda et al., 1994). This mutation is
elieved to account for 63% of the mutant alleles in Por-
uguese patients with GD. Although the N370S mutation was
hree times more frequent in the PD group when compared to
ontrols, we did not have sufficient power to identify a statis-
ically significant association analyzing this mutation alone
p = 0.079; OR 3.3; 95% CI 0.75–13.4). Mutation N396T,
ncountered in 5 subjects in this study, was first identified in
ortugal and has proven to be a relatively common mutation
n this population (Amaral et al., 2000).
This study substantiates the need to sequence GBA in
on-Ashkenazi cohorts in order to accurately determine the
requency of mutations in this gene. Had we screened only
or common Gaucher mutations, we would have missed 43%
f the mutant alleles in this population.
The association of GBA mutations with PD in the Por-
uguese population is particularly interesting when it is noted
hat the mutation driving this association is one associ-
ted with Jewish ancestry, and that another PD causing
utation, p.G2019S of LRRK2, underlying ∼6% of Por-
uguese PD cases (Bras et al., 2005), is also associated with
shkenazi Jewish ancestry; these data clearly illustrate the
ontribution of Jewish ancestry to the modern Portuguese
opulation.
In summary using a cohort with a different and defined eth-
icity, we demonstrate that GBA mutations are significantly
ore common in patients with PD than in neurologically
ormal controls. These findings illustrate that the identifica-
ion of such an association requires large sample series, evenglucocerebrosidase mutations in Parkinson disease patients from
1.016
hen using populations where GBA mutations are enriched;
hus detection of such an association in populations with
on-Ashkenazi ancestry is likely to require thousands of sam-
les.
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